Seres Therapeutics (MCRB) Total Non-Current Liabilities (2014 - 2026)

Seres Therapeutics has reported Total Non-Current Liabilities for 13 years, with the latest figure at $89.0 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 20.43% year-over-year to $89.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $89.0 million (down 20.43% YoY) and the FY2025 annual result came in at $91.9 million, down 26.0% from the prior year.
• Total Non-Current Liabilities fell to $89.0 million in Q1 2026 per MCRB's latest filing, from $91.9 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $408.8 million in Q2 2024 and troughed at $89.0 million in Q1 2026.
• A 5-year average of $243.1 million and a median of $243.3 million in 2022 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities soared 58.86% in 2022, then slumped 73.36% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $336.6 million in 2022, then increased by 19.39% to $401.8 million in 2023, then slumped by 69.09% to $124.2 million in 2024, then declined by 26.0% to $91.9 million in 2025, then dropped by 3.18% to $89.0 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $89.0 million, $91.9 million, and $97.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.